165 related articles for article (PubMed ID: 37621812)
1. Cannabidiol and Tetrahydrocannabinol Use in Parkinson's Disease: An Observational Pilot Study.
Sousa A; DiFrancisco-Donoghue J
Cureus; 2023 Jul; 15(7):e42391. PubMed ID: 37621812
[TBL] [Abstract][Full Text] [Related]
2. Higher Risk, Higher Reward? Self-Reported Effects of Real-World Cannabis Use in Parkinson's Disease.
Holden SK; Domen CH; Sillau S; Liu Y; Leehey MA
Mov Disord Clin Pract; 2022 Apr; 9(3):340-350. PubMed ID: 35392299
[TBL] [Abstract][Full Text] [Related]
3. Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
Domen CH; Sillau S; Liu Y; Adkins M; Rajkovic S; Bainbridge J; Sempio C; Klawitter J; Leehey MA
Mov Disord; 2023 Jul; 38(7):1341-1346. PubMed ID: 37212386
[TBL] [Abstract][Full Text] [Related]
4. Knowledge of Tetrahydrocannabinol and Cannabidiol Levels Among Cannabis Consumers in the United States and Canada.
Hammond D; Goodman S
Cannabis Cannabinoid Res; 2022 Jun; 7(3):345-354. PubMed ID: 33998866
[No Abstract] [Full Text] [Related]
5. Effects of cannabidiol in cannabis flower: Implications for harm reduction.
Gibson LP; Karoly HC; Ellingson JM; Klawitter J; Sempio C; Squeri JE; Bryan AD; Bidwell LC; Hutchison KE
Addict Biol; 2022 Jan; 27(1):e13092. PubMed ID: 34467598
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids in Treating Parkinson's Disease Symptoms: A Systematic Review of Clinical Studies.
Varshney K; Patel A; Ansari S; Shet P; Panag SS
Cannabis Cannabinoid Res; 2023 Oct; 8(5):716-730. PubMed ID: 37253174
[No Abstract] [Full Text] [Related]
7. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
[TBL] [Abstract][Full Text] [Related]
8. Homegrown perceptions about the medical use and potential abuse of CBD and THC.
McFadden BR; Malone T
Addict Behav; 2021 Apr; 115():106799. PubMed ID: 33387977
[TBL] [Abstract][Full Text] [Related]
9. An assessment of qualitative and quantitative cannabinoids analysis in selected commercially available cannabis oils in Argentina.
Fernández N; Cappello MG; Quiroga PN
Forensic Sci Int; 2023 Aug; 349():111762. PubMed ID: 37392612
[TBL] [Abstract][Full Text] [Related]
10. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
11. Use of Tetrahydrocannabinol and Cannabidiol Products in the Perioperative Period Around Primary Unilateral Total Hip and Knee Arthroplasty.
Runner RP; Luu AN; Nassif NA; Scudday TS; Patel JJ; Barnett SL; Gorab RS
J Arthroplasty; 2020 Jun; 35(6S):S138-S143. PubMed ID: 32173619
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Safety, and Tolerability of a Medicinal Cannabis Formulation in Patients with Chronic Non-cancer Pain on Long-Term High Dose Opioid Analgesia: A Pilot Study.
Bonomo Y; Norman A; Collins L; O'Neill H; Galettis P; Trinca J; Strauss N; Martin J; Castle D
Pain Ther; 2022 Mar; 11(1):171-189. PubMed ID: 34921662
[TBL] [Abstract][Full Text] [Related]
13. Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?
Crippa JAS; Hallak JEC; Zuardi AW; Guimarães FS; Tumas V; Dos Santos RG
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):121-133. PubMed ID: 30706171
[TBL] [Abstract][Full Text] [Related]
14. Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental
Bidwell LC; Martin-Willett R; Skrzynski C; Lisano J; Ortiz Torres M; Giordano G; Hutchison KE; Bryan AD
Cannabis Cannabinoid Res; 2024 Jan; ():. PubMed ID: 38252547
[No Abstract] [Full Text] [Related]
15. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
[TBL] [Abstract][Full Text] [Related]
16. Substituting Cannabidiol for Opioids and Pain Medications Among Individuals With Fibromyalgia: A Large Online Survey.
Boehnke KF; Gagnier JJ; Matallana L; Williams DA
J Pain; 2021 Nov; 22(11):1418-1428. PubMed ID: 33992787
[TBL] [Abstract][Full Text] [Related]
17. A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol.
Bergeria CL; Strickland JC; Spindle TR; Kalaba M; Satyavolu PU; Feldner M; Vandrey R; Bonn-Miller M; Peters EN; Weerts E
Exp Clin Psychopharmacol; 2023 Apr; 31(2):312-317. PubMed ID: 35467921
[TBL] [Abstract][Full Text] [Related]
18. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
